Diligence memo · auto-generated · as of July 2, 2026
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Biosortia Pharmaceuticals, Inc. operates in Pharmaceuticals, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biosortia Pharmaceuticals, Inc. has raised $10M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.9M on 2013-06-14.
Most recent recorded round closed around 2019-10-25.
Valuation (modeled)modeled
Provath models Biosortia Pharmaceuticals, Inc. at approximately $26M (range $510K–$201M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.45× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 6.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 55% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Wiesman Capital & Co., LLC, Curzion Pharmaceuticals, Inc., Providence Therapeutics Inc., EnBiotix, Inc., Metuchen Pharmaceuticals, LLC.
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.